Tumor-homing exosomes enable targeted delivery of siRNA and isoimperatorin for overcoming BTK inhibitor resistance in DLBCL
Source abstract
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma, but over one-third of patients relapse or develop refractory disease after first-line therapy. Novel therapeutic strategies are required to address persistent unmet clinical needs for DLBCL. This study aimed to develop an exosome-based drug delivery system for the targeted combination therapy of siRNA against Bruton's tyrosine kinase (BTK, an established therapeutic target in B cell lymphomas) and isoimperatorin (ISOIM, an active natural furanocoumarin showing anti-tumor effects) in DLBCL. Tumor exosomes were isolated as the delivery carrier. ISOIM/siBTK@Exosome was prepared by encapsulating ISOIM and si-BTK into exosome using electroporation. Cellular uptake, immune escape, targeted delivery efficiency, anti-lymphoma activity and biosafety of ISOIM/siBTK@Exosome were evaluated in two DLBCL cell lines and in tumor-bearing mice. ISOIM/siBTK@Exosome displayed significant anti-lymphoma activity compared to ISOIM@Exosome or siBTK@Exosome alone, demonstrating synergistic therapeutic role of ISOIM and si-BTK. Besides, ISOIM/siBTK@Exosome can accelerate T cells activation and prevent macrophage M2 polarization in vitro. Administration of ISOIM/siBTK@Exosome to tumor-bearing mice significantly inhibited tumor growth and prolonged survival. The ISOIM/siBTK@Exosome was biocompatible and biosafe in vivo without damage on the major organs in H&E staining. The prepared ISOIM/siBTK@Exosome may provide novel targeted therapeutic strategy to be applied in the clinical management of patients with DLBCL.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Extracellular vesicles in disease · Cell Adhesion Molecules Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (65)
Show source-provided references
1. Non-Hodgkin lymphoma10.1016/S0140-6736(16)32407-2 ↗
2. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
3. Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 201910.18632/aging.204006 ↗
4. Diffuse large B-cell lymphoma10.1002/hon.3202 ↗
5. How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma10.1182/blood.2024024788 ↗
6. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis10.1038/s41375-023-02120-7 ↗
7. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma10.1038/nm.3884 ↗
8. CD30 protects EBV-positive diffuse large B-cell lymphoma cells against mitochondrial dysfunction through BNIP3-mediated mitophagy10.1016/j.canlet.2024.216616 ↗
9. Targeting the B cell receptor pathway in non-Hodgkin lymphoma10.1080/13543784.2018.1482273 ↗
10. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma10.1016/j.ctrv.2018.01.002 ↗
11. Role of Bruton's tyrosine kinase in B cells and malignancies10.1186/s12943-018-0779-z ↗
12. Bruton tyrosine kinase inhibitors in B-cell malignancies: their use and differential features10.1007/s11523-021-00857-8 ↗
13. Bruton's tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials10.3390/molecules28052400 ↗
14. Abivertinib, a novel BTK inhibitor: anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia10.1016/j.canlet.2019.07.008 ↗
15. Dermatological toxicities of Bruton's tyrosine kinase inhibitors10.1007/s40257-020-00535-x ↗
16. Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors10.1056/NEJMoa2114110 ↗
17. Enhancing siRNA cancer therapy: multifaceted strategies with lipid and polymer-based carrier systems10.1016/j.ijpharm.2024.124545 ↗
18. Challenges and opportunities for siRNA-based cancer treatment10.1016/j.canlet.2016.03.045 ↗
19. The landscape of nanoparticle-based siRNA delivery and therapeutic development10.1016/j.ymthe.2024.01.005 ↗
20. Nanoparticles and siRNA: a new era in therapeutics?10.1016/j.phrs.2024.107102 ↗
21. Exosome-based nanoparticles and cancer immunotherapy10.1016/j.biopha.2024.117296 ↗
22. Engineering exosomes for targeted drug delivery10.7150/thno.52570 ↗
23. Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake10.1016/j.jconrel.2022.05.027 ↗
24. Exosome-like systems: nanotechnology to overcome challenges for targeted cancer therapies10.1016/j.canlet.2023.216151 ↗
25. Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors10.1016/j.actbio.2022.01.005 ↗
26. Natural products: promising resources for cancer drug discovery10.2174/187152012798764697 ↗
27. Antiviral activity of isoimperatorin against influenza A virus in vitro and its inhibition of neuraminidase10.3389/fphar.2021.657826 ↗
28. Isoimperatorin inhibits angiogenesis by suppressing VEGFR2 signaling pathway
29. Isoimperatorin alleviates lipopolysaccharide-induced periodontitis by downregulating ERK1/2 and NF-κB pathways
30. Isoimperatorin down-regulates epithelial mesenchymal transition through modulating NF-κB signaling and CXCR4 expression in colorectal and hepatocellular carcinoma cells10.1016/j.cellsig.2022.110433 ↗
31. Isoimperatorin induces apoptosis of the SGC-7901 human gastric cancer cell line via the mitochondria-mediated pathway10.3892/ol.2016.5387 ↗
32. Effects of isoimperatorin on proliferation and apoptosis of human gastric carcinoma cells
33. Apoptotic effect of isoimpertorin via inhibition of c-Myc and SIRT1 signaling Axis10.3390/ijms25084248 ↗
34. Construction of homologous cancer cell membrane camouflage in a nano-drug delivery system for the treatment of lymphoma10.1186/s12951-020-00738-8 ↗
35. Controlled drug delivery systems: past forward and future back10.1016/j.jconrel.2014.03.054 ↗
36. Liposomal drug delivery systems: from concept to clinical applications10.1016/j.addr.2012.09.037 ↗
37. Targeted drug delivery strategies for precision medicines10.1038/s41578-020-00269-6 ↗
38. Drug delivery to the central nervous system10.1038/s41578-021-00394-w ↗
39. The blood–brain barrier: structure, regulation and drug delivery10.1038/s41392-023-01481-w ↗
40. Safe nanoparticles: are we there yet?10.3390/ijms22010385 ↗
41. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system10.1016/0169-409X(95)00039-A ↗
42. Zwitterionic‐coated “stealth” nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system10.1002/smll.201303540 ↗
43. Exosome engineering in cell therapy and drug delivery10.1007/s10787-022-01115-7 ↗
44. Extracellular vesicles as a next-generation drug delivery platform10.1038/s41565-021-00931-2 ↗
45. Functionalized exosome harboring bioactive molecules for cancer therapy10.1016/j.canlet.2020.05.036 ↗
46. Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs10.7150/thno.39434 ↗
47. Advances in exosome-based drug delivery and tumor targeting: from tissue distribution to intracellular fate10.2147/IJN.S281890 ↗
48. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis10.1016/j.cell.2009.05.046 ↗
49. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis10.1016/j.biomaterials.2017.01.004 ↗
50. Exosomal CD47 plays an essential role in immune evasion in ovarian cancer10.1158/1541-7786.MCR-20-0956 ↗
51. Extracellular vesicles: a rising star for therapeutics and drug delivery10.1186/s12951-023-01973-5 ↗
52. Tumor cell-derived exosomes deliver TIE2 protein to macrophages to promote angiogenesis in cervical cancer10.1016/j.canlet.2022.01.005 ↗
53. Cancer cell-derived exosome based dual-targeted drug delivery system for non-small cell lung cancer therapy10.1016/j.colsurfb.2024.114141 ↗
54. Synergistic phototherapy-molecular targeted therapy combined with tumor exosome nanoparticles for oral squamous cell carcinoma treatment10.3390/pharmaceutics16010033 ↗
55. Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy10.1038/s41467-019-11718-4 ↗
56. Drug loading techniques for exosome-based drug delivery systems
57. Current strategies for exosome cargo loading and targeting delivery10.3390/cells12101416 ↗
58. Kumar · 2019
59. Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy10.1186/s12943-024-02057-0 ↗
60. Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: phase 2 proof-of-concept study10.1158/1078-0432.CCR-21-2547 ↗
61. A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells10.1080/2162402X.2016.1151592 ↗
62. Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma10.1038/s41467-024-46220-z ↗
63. Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count10.1186/s12885-019-6208-x ↗
64. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial10.3324/haematol.2014.113472 ↗
65. Inflammatory cells in diffuse large B cell lymphoma10.3390/jcm9082418 ↗